Transgene S.a.

Institut National De La Sante Et De La Recherche Medicale

Nourredine Himoudi

Anne Fournillier

Genevieve Inchauspe

Geneviève Inchauspe

Perrine Martin

The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.

Peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus

Novel peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least the amino acid sequence of SEQ ID NO 45, a peptide C having at least the amino acid sequence of SEQ ID NO 127, and a peptide D having at least the amino acid sequence of SEQ ID NO 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

Peptide compositions and their use against the hepatitis C virus

Peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N&#xb0; 1, a peptide B having at least the amino acid sequence of SEQ ID N&#xb0; 45, a peptide C having at least the amino acid sequence of SEQ ID N&#xb0; 127, and a peptide D having at least the amino acid sequence of SEQ ID N&#xb0; 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

Nucleic acid compositions and their use against the hepatitic C virus

The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N1, a peptide B having at least the amino acid sequence of SEQ ID N45, a peptide C having at least the amino acid sequence of SEQ ID N127, a peptide D having at least the amino acid sequence of SEQ. ID N174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

Growing community of inventors

Lyons, France

Nourredine Himoudi